Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIRCETTE vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women aged ≥15 years who have reached menarche and desire contraception
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethinyl estradiol: primarily metabolized via CYP3A4; undergoes first-pass hepatic metabolism, conjugated to sulfate and glucuronide. Desogestrel: prodrug converted to active metabolite etonogestrel via CYP2C9 and CYP3A4; further metabolized by reduction and glucuronidation.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Desogestrel: >95% (albumin, SHBG); ethinyl estradiol: >97% (albumin)
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Desogestrel: 1.5 L/kg; ethinyl estradiol: 2.9 L/kg
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Desogestrel (as etonogestrel): 76% (oral); ethinyl estradiol: 55% (oral, variable due to first-pass metabolism)
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No specific dose adjustment recommended. Use with caution in severe renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in severe hepatic disease (Child-Pugh class C) or liver tumors. For mild to moderate impairment (Child-Pugh A-B), use with caution; contraindicated if liver function tests are persistently abnormal.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not indicated in prepubertal females. Safety and efficacy in postmenarchal adolescents established based on adult studies.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Contraindicated in postmenopausal women. Not indicated for use in elderly due to lack of efficacy for contraception.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events from COC use, especially in women >35 years old who smoke ≥15 cigarettes/day. Do not prescribe to women who smoke and are over 35.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thrombotic disorders (VTE, MI, stroke), especially in smokers and women with hypertension or other risk factors.,Liver disease: discontinue if jaundice or impaired liver function develops.,Elevated blood pressure: monitor and discontinue if hypertension develops.,Gallbladder disease: possible increased risk.,Carbohydrate and lipid metabolism: monitor in diabetic or hyperlipidemic patients.,Headache: may exacerbate migraine or cause new-onset headache.,Uterine bleeding: irregular bleeding may occur.,Depression: discontinue if significant depression occurs.,Ocular effects: discontinue if sudden partial/complete vision loss occurs.,Carcinoma: possible increased risk of breast/cervical cancer, but evidence uncertain.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Carcinoma of endometrium or other known/suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component,Smoking and age >35 years,Migraine with aura (current or history) in women over 35
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No significant food interactions known; however, grapefruit juice may increase estrogen levels via CYP3A4 inhibition, though clinical significance is low. Avoid St. John's wort as it induces metabolism of ethinyl estradiol and desogestrel, potentially reducing contraceptive efficacy.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester exposure associated with congenital anomalies (cardiovascular, limb reduction, neural tube defects). Second/third trimester exposure may cause fetal adrenal suppression, virilization of female fetus, and metabolic disturbances.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Excreted into breast milk. M/P ratio unknown. Potential for serious adverse effects in nursing infant (adrenal suppression, hormonal imbalance). Contraindicated during breastfeeding per manufacturer.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No dose adjustments applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) would theoretically require dose increase, but use is not recommended.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
Mircette is a monophasic oral contraceptive containing 0.15 mg desogestrel and 0.02 mg ethinyl estradiol. It has a shorter hormone-free interval (2 days of placebo) than traditional 7-day placebo regimens, which may reduce breakthrough ovulation and improve suppression of ovarian activity. Counsel patients that the first 7 days of the initial cycle may require a backup method. Desogestrel has low androgenicity and may improve acne. Use with caution in patients with migraine with aura or increased cardiovascular risk.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one tablet at the same time daily; missed pills increase pregnancy risk.,If you miss a pill, refer to the package insert for instructions; use backup contraception if needed.,Mircette may reduce menstrual bleeding and cramping; do not skip pills during withdrawal bleeding.,Smoking while on this pill increases risk of blood clots, especially in women over 35.,Some antibiotics and anticonvulsants may reduce effectiveness; inform your healthcare provider of all medications.,Do not take if you have a history of blood clots, certain cancers, or liver disease.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIRCETTE vs ALTAVERA, answered by our medical review team.
MIRCETTE is a Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIRCETTE and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIRCETTE is: One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIRCETTE and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIRCETTE is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester exposure associated with congenital anomalies (cardiovascular, limb reduction, neural tube defects). Second/. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.